Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
Not yet recruiting · NCT07303881 · Registry updated 2025-12-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer | Hemic and Lymphatic Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, hematologic disorder, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2025-12-26 | NCT07303881 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The First Affiliated Hospital of Guangzhou Medical University | 95 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| First Affiliated Hospital of Guangzhou Medical College | Guangzhou | China | 1 |